Investment vehicle provides diversified exposure to real-world assets and expected to reduce portfolio volatility Strategic allocation aligns with Silo’s objective of generating yield while maintaining a hedge against downside risk New York, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has selected Alphaledger/Simplify Target 12% Distribution F ...